News | November 09, 2025
Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
Sumatriptan injection is indicated in adults for the acute treatment of migraine
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Subscribe To Our Newsletter & Stay Updated
